Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Veritas In Silico Inc. ( (JP:130A) ) is now available.
Veritas In Silico Inc. reported a sharp year-on-year decline in business revenue to ¥17 million for the first quarter ended March 31, 2026, with operating and ordinary losses widening to around ¥120 million and a net loss deepening to ¥256 million. Total assets fell to ¥1,785 million and the equity ratio slipped to 85.6%, while the company maintained its policy of paying no dividends for the current fiscal year.
For the full year ending December 31, 2026, the company forecasts business revenue of ¥113 million, a 24.2% increase, but expects a significantly larger net loss of ¥567 million, implying a continued investment or development phase. The unchanged guidance and voluntary review of its Japanese financial statements suggest management is prioritizing transparency while navigating persistent losses, a key concern for shareholders monitoring dilution risk and balance-sheet strength.
More about Veritas In Silico Inc.
Veritas In Silico Inc., listed on the Tokyo Stock Exchange, operates in the life sciences and biotechnology sector, focusing on computational and in silico technologies for drug discovery and related applications. The company’s business model centers on generating revenue from specialized research services and platforms, positioning it in a niche segment of Japan’s biotech and pharmaceutical support market.
Average Trading Volume: 32,530
Technical Sentiment Signal: Sell
Current Market Cap: Yen3.01B
Find detailed analytics on 130A stock on TipRanks’ Stock Analysis page.